Mesenchymal Stem Cell Composition for Soft Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for soft tissue injuries, such as wounds, are limited by rapid depletion of growth factors, uncontrolled release of growth factors, low cellular engraftment due to hypoxic stress, and lack of biocompatibility, necessitating an improved approach for enhanced repair and regeneration.
Innovation Solution
A composition comprising a substantially pure mesenchymal stem cells population seeded on a biocompatible matrix, specifically derived from adipose tissue and comprising less than 25% fibroblasts, which is undifferentiated and derived from the subject to be treated, providing improved survival and proliferation under hypoxic conditions and enhanced release of pro-angiogenic factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If local injection of growth factors is used, then growth factors are delivered to the injury site, but the local concentration is rapidly depleted and bioactivity is lost
Solution Approach 1:
The patent uses a biocompatible matrix as an intermediary carrier to deliver growth factors and stem cells to the injury site. This matrix sustains the release of growth factors over time, preventing rapid depletion and maintaining bioactivity. The matrix acts as a mediator between the growth factors and the injury site, enabling controlled and prolonged delivery.
Solution Approach 2:
The patent employs stem cells that are pre-loaded with growth factors or primed to secrete growth factors upon implantation. This preliminary preparation ensures that growth factors are released in a controlled manner at the injury site, extending their bioactivity duration and preventing rapid depletion.
2Quantity of substance
If direct implantation of decellularized extracellular matrix is used, then native growth factors are delivered, but uncontrolled release occurs and biocompatibility is compromised due to xenogenic origins
Solution Approach 1:
The patent changes the origin parameter of the matrix from xenogenic to autologous or allogeneic sources, improving biocompatibility. It also modifies the release kinetics parameter by using engineered matrices that provide controlled release rather than uncontrolled release, ensuring reliable and safe delivery of growth factors.
Solution Approach 2:
The patent uses a biocompatible matrix with specific local properties engineered to provide controlled release of growth factors at the injury site. The matrix is designed with specific porosity, degradation rate, and affinity characteristics that enable localized and controlled delivery, improving both biocompatibility and reliability.
3Quantity of substance
If differentiated muscle cells are transplanted, then muscle tissue is provided, but cellular engraftment is low due to hypoxic stress
Solution Approach 1:
The patent uses stem cells that possess inherent resistance to hypoxic stress and the ability to self-renew and differentiate. These cells can survive and thrive in the hypoxic environment of the injury site without external support, providing self-service capability that overcomes the limitations of differentiated muscle cells.
Solution Approach 2:
The patent changes the cellular parameter from differentiated muscle cells to stem cells, which have different physiological properties including higher resistance to hypoxic stress. This parameter change enables better cellular engraftment and survival in the challenging hypoxic environment of soft tissue injuries.
4Quantity of substance
If non-pure mesenchymal stem cells population is used, then cell quantity is sufficient, but repair and regeneration efficacy is reduced
Solution Approach 1:
The patent extracts and removes non-mesenchymal stem cells from the cell population through purification steps, obtaining a substantially pure mesenchymal stem cells population. This extraction of unwanted cell types ensures that the therapeutic effect is maximized by eliminating cells that do not contribute to repair and regeneration.
Solution Approach 2:
The patent changes the purity parameter of the stem cells population from non-pure to substantially pure (greater than 90% mesenchymal stem cells). This parameter change significantly improves repair and regeneration efficacy while maintaining sufficient cell quantity for therapeutic application.
Data Source
Figure 1~2D
Figure 3~4
Figure 5A~6
AI summary
The present invention relates to a composition comprising a biocompatible matrix and a substantially pure mesenchymal stem cells population. The present invention also relates to its use for treating soft tissue injuries.